{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:10:06Z","timestamp":1782526206569,"version":"3.54.5"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-024-09553-x","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:32:11Z","timestamp":1734492731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review"],"prefix":"10.1007","volume":"73","author":[{"given":"Vanshika","family":"Rustagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradheya R. R.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandni","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Jamwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash Kumar","family":"Bhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrakant K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"9553_CR1","doi-asserted-by":"crossref","unstructured":"Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China. JAMA. 2020 [cited 2023 Nov 5];323:709. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2760500.","DOI":"10.1001\/jama.2020.1097"},{"key":"9553_CR2","doi-asserted-by":"crossref","unstructured":"Jee Y. WHO International Health Regulations Emergency Committee for the COVID-19 outbreak. Epidemiol Health. 2020 [cited 2023 Nov 5];42:e2020013. Available from: http:\/\/e-epih.org\/journal\/view.php?doi=10.4178\/epih.e2020013.","DOI":"10.4178\/epih.e2020013"},{"key":"9553_CR3","doi-asserted-by":"crossref","unstructured":"Worobey M, Pekar J, Larsen BB, Nelson MI, Hill V, Joy JB, et al. The emergence of SARS-CoV-2 in Europe and North America. Science. 2020 [cited 2023 Nov 5];370:564\u201370. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32912998.","DOI":"10.1126\/science.abc8169"},{"key":"9553_CR4","unstructured":"Rao DKS. Impact of Covid-19 in 3 years. Times of India. 2023."},{"key":"9553_CR5","doi-asserted-by":"crossref","unstructured":"Pullano G, Valdano E, Scarpa N, Rubrichi S, Colizza V. Evaluating the effect of demographic factors, socioeconomic factors, and risk aversion on mobility during the COVID-19 epidemic in France under lockdown: a population-based study. Lancet Digit Health. 2020;2:e638\u201349. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589750020302430.","DOI":"10.1016\/S2589-7500(20)30243-0"},{"key":"9553_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cca.2020.08.013","volume":"510","author":"P Kumari","year":"2020","unstructured":"Kumari P, Singh A, Ngasainao MR, Shakeel I, Kumar S, Lal S, et al. Potential diagnostics and therapeutic approaches in COVID-19. Clin Chim Acta. 2020;510:488\u201397.","journal-title":"Clin Chim Acta"},{"key":"9553_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.15585\/mmwr.mm7012e1","volume":"70","author":"MM Hughes","year":"2021","unstructured":"Hughes MM, Wang A, Grossman MK, Pun E, Whiteman A, Deng L, et al. County-level COVID-19 vaccination coverage and social vulnerability \u2014 United States, December 14, 2020\u2013March 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:431\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9553_CR8","doi-asserted-by":"crossref","unstructured":"Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist. 2021 [cited 2023 Nov 5];Volume 14:3459\u201376. Available from: https:\/\/www.dovepress.com\/overview-of-the-main-anti-sars-cov-2-vaccines-mechanism-of-action-effi-peer-reviewed-fulltext-article-IDR.","DOI":"10.2147\/IDR.S315727"},{"key":"9553_CR9","doi-asserted-by":"crossref","unstructured":"Rosenfeld R, Noy-Porat T, Mechaly A, Makdasi E, Levy Y, Alcalay R, et al. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody. Nat Commun. 2021 [cited 2023 Nov 5];12:944. Available from: https:\/\/www.nature.com\/articles\/s41467-021-21239-8.","DOI":"10.1038\/s41467-021-21239-8"},{"key":"9553_CR10","doi-asserted-by":"crossref","unstructured":"Pilkington V, Keestra SM, Hill A. Global COVID-19 Vaccine inequity: failures in the first year of distribution and potential solutions for the future. Front Public Health. 2022 [cited 2023 Nov 5];10:821117. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35321196.","DOI":"10.3389\/fpubh.2022.821117"},{"key":"9553_CR11","doi-asserted-by":"publisher","unstructured":"Nagar S, Talwar C, Haider S, Puri A, Ponnusamy K, Gupta M, et al. Phylogenetic relationships and potential functional attributes of the genus Parapedobacter: a member of family Sphingobacteriaceae. Front Microbiol. 2020;11. https:\/\/doi.org\/10.3389\/fmicb.2020.01725.","DOI":"10.3389\/fmicb.2020.01725"},{"key":"9553_CR12","doi-asserted-by":"crossref","unstructured":"Moti UG, Goon D Ter. Novel coronavirus disease: a delicate balancing act between health and the economy. Pak J Med Sci. 2020 [cited 2023 Nov 5];36:S134. Available from: https:\/\/www.pjms.org.pk\/index.php\/pjms\/article\/view\/2751.","DOI":"10.12669\/pjms.36.COVID19-S4.2751"},{"key":"9553_CR13","doi-asserted-by":"publisher","unstructured":"Costello EJ, Angold A. Developmental epidemiology. In: Developmental psychopathology. 2016. p. 1\u201335. https:\/\/doi.org\/10.1002\/9781119125556.devpsy103.","DOI":"10.1002\/9781119125556.devpsy103"},{"key":"9553_CR14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/encyclopedia2030090","volume":"2","author":"G Calcaterra","year":"2022","unstructured":"Calcaterra G, Bassareo PP, Barilla F, Romeo F, de Gregorio C, Mehta P, et al. Syndemic: a synergistic anthropological approach to the COVID-19 pandemic. Encyclopedia. 2022;2:1344\u201356.","journal-title":"Encyclopedia"},{"key":"9553_CR15","unstructured":"WHO team, COVID-19 weekly epidemiological update, Edition 162 https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update---22-december-2023, 2023"},{"key":"9553_CR16","doi-asserted-by":"publisher","first-page":"15531","DOI":"10.1038\/s41598-021-94719-y","volume":"11","author":"DA Swan","year":"2021","unstructured":"Swan DA, Bracis C, Janes H, Moore M, Matrajt L, Reeves DB, et al. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Sci Rep. 2021;11:15531.","journal-title":"Sci Rep"},{"key":"9553_CR17","doi-asserted-by":"crossref","unstructured":"Yang Z, Zhang S, Tang Y-P, Zhang S, Xu D-Q, Yue S-J, et al. Clinical characteristics, transmissibility, pathogenicity, susceptible populations, and re-infectivity of prominent COVID-19 variants. Aging Dis. 2022 [cited 2023 Nov 5];13:402. Available from: http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2021.1210.","DOI":"10.14336\/AD.2021.1210"},{"key":"9553_CR18","doi-asserted-by":"publisher","unstructured":"Liu DX, Liang JQ, Fung TS. Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). In: Encyclopedia of virology. Elsevier; 2021. p. 428\u201340. https:\/\/doi.org\/10.1016\/B978-0-12-809633-8.21501-X.","DOI":"10.1016\/B978-0-12-809633-8.21501-X"},{"key":"9553_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","volume":"26","author":"N Petrosillo","year":"2020","unstructured":"Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:729\u201334.","journal-title":"Clin Microbiol Infect"},{"key":"9553_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbrc.2020.10.102","volume":"538","author":"M Giovanetti","year":"2021","unstructured":"Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. Evolution patterns of SARS-CoV-2: snapshot on its genome variants. Biochem Biophys Res Commun. 2021;538:88\u201391.","journal-title":"Biochem Biophys Res Commun"},{"key":"9553_CR21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812-827.e19.","journal-title":"Cell"},{"key":"9553_CR22","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1073\/pnas.0506735102","volume":"102","author":"SKP Lau","year":"2005","unstructured":"Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi H-W, Wong BHL, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci. 2005;102:14040\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"310","key":"9553_CR23","first-page":"676","volume":"2005","author":"W Li","year":"1979","unstructured":"Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 1979;2005(310):676\u20139.","journal-title":"Science"},{"key":"9553_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006698","volume":"13","author":"B Hu","year":"2017","unstructured":"Hu B, Zeng L-P, Yang X-L, Ge X-Y, Zhang W, Li B, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017;13: e1006698.","journal-title":"PLoS Pathog"},{"key":"9553_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12250-015-3703-3","volume":"31","author":"M-N Wang","year":"2016","unstructured":"Wang M-N, Zhang W, Gao Y-T, Hu B, Ge X-Y, Yang X-L, et al. Longitudinal surveillance of SARS-like coronaviruses in bats by quantitative real-time PCR. Virol Sin. 2016;31:78\u201380.","journal-title":"Virol Sin"},{"key":"9553_CR26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/acs.jproteome.0c00129","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zheng W, Huang X, Bell EW, Zhou X, Zhang Y. protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1. J Proteome Res. 2020;19:1351\u201360.","journal-title":"J Proteome Res"},{"key":"9553_CR27","unstructured":"Zhou Y, Zhang S, Chen J, Wan C, Zhao W, Zhang B. Analysis of variation and evolution of SARS-CoV-2 genome. Nan Fang Yi Ke Da Xue Xue Bao. 2020 [cited 2023 Nov 5];40:152\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32376535."},{"key":"9553_CR28","first-page":"215","volume":"49","author":"J Chen","year":"2020","unstructured":"Chen J, Liu D, Liu Li, Liu P, Qingnian Xu, Xia Lu, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49:215\u20139.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"9553_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450\u20132.","journal-title":"Nat Med"},{"key":"9553_CR30","doi-asserted-by":"crossref","unstructured":"Air GM. Influenza virus\u2013glycan interactions. Curr Opin Virol. 2014 [cited 2023 Nov 5];7:128\u201333. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625714001436.","DOI":"10.1016\/j.coviro.2014.06.004"},{"key":"9553_CR31","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.2174\/1381612827666210125160703","volume":"27","author":"IK Singh","year":"2021","unstructured":"Singh IK, Kumari P, Mittal P, Kumar A, Singal B, Hasan GM, et al. Emerging therapeutic approaches to COVID-19. Curr Pharm Des. 2021;27:3370\u201388.","journal-title":"Curr Pharm Des"},{"key":"9553_CR32","doi-asserted-by":"crossref","unstructured":"Hart WS, Miller E, Andrews NJ, Waight P, Maini PK, Funk S, et al. Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. Lancet Infect Dis. 2022 [cited 2023 Nov 5];22:603\u201310. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35176230.","DOI":"10.1016\/S1473-3099(22)00001-9"},{"key":"9553_CR33","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Rodr\u00edguez D, Gonzalez-Parra G, Villanueva R-J. Analysis of key factors of a SARS-CoV-2 vaccination program: a mathematical modeling approach. Epidemiologia. 2021 [cited 2023 Nov 5];2:140\u201361. Available from: https:\/\/www.mdpi.com\/2673-3986\/2\/2\/12.","DOI":"10.3390\/epidemiologia2020012"},{"key":"9553_CR34","doi-asserted-by":"crossref","unstructured":"Rustagi V, Bajaj M, Tanvi, Singh P, Aggarwal R, AlAjmi MF, et al. Analyzing the effect of vaccination over COVID cases and deaths in Asian countries using machine learning models. Front Cell Infect Microbiol. 2021 [cited 2023 Nov 5];11:806265. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35223534.","DOI":"10.3389\/fcimb.2021.806265"},{"key":"9553_CR35","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang Y, Kang J-Y, Chen S, He Y, Han B, et al. Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2. Cell Discov. 2021 [cited 2023 Nov 5];7:44. Available from: https:\/\/www.nature.com\/articles\/s41421-021-00282-1","DOI":"10.1038\/s41421-021-00282-1"},{"key":"9553_CR36","doi-asserted-by":"crossref","unstructured":"Eales O, Page AJ, Tang SN, Walters CE, Wang H, Haw D, et al. SARS-CoV-2 lineage dynamics in England from January to March 2021 inferred from representative community samples. medRxiv. 2021 [cited 2023 Nov 5];2021.05.08.21256867. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.08.21256867v1.","DOI":"10.1101\/2021.05.08.21256867"},{"key":"9553_CR37","doi-asserted-by":"crossref","unstructured":"Gr\u00e4f T, Bello G, Venas TMM, Pereira EC, Paix\u00e3o ACD, Appolinario LR, et al. Identification of a novel SARS-CoV-2 P.1 sub-lineage in Brazil provides new insights about the mechanisms of emergence of variants of concern. Virus Evol. 2021 [cited 2023 Nov 5];7:1\u201310. Available from: https:\/\/academic.oup.com\/ve\/article\/doi\/10.1093\/ve\/veab091\/6462077.","DOI":"10.1093\/ve\/veab091"},{"key":"9553_CR38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.7150\/ijbs.68973","volume":"18","author":"M Zhang","year":"2022","unstructured":"Zhang M, Liang Y, Yu D, Du B, Cheng W, Li L, et al. A systematic review of vaccine breakthrough infections by SARS-CoV-2 Delta variant. Int J Biol Sci. 2022;18:889\u2013900.","journal-title":"Int J Biol Sci"},{"key":"9553_CR39","doi-asserted-by":"crossref","unstructured":"Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022 [cited 2023 Nov 5];11:337\u201343. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/22221751.2021.2022440.","DOI":"10.1080\/22221751.2021.2022440"},{"key":"9553_CR40","unstructured":"Sunainaa Chadha. Explainer: why WHO named latest Covid variant, first detected in South Africa, Omicro. 2021."},{"key":"9553_CR41","doi-asserted-by":"crossref","unstructured":"Williams AH, Zhan CG. Fast prediction of binding affinities of the Sars-CoV-2 spike protein mutant N501Y (UK variant) with ACE2 and miniprotein drug candidates. J Phys Chem B. 2021 [cited 2023 Nov 5];125:4330\u20136. Available from: https:\/\/pubs.acs.org\/doi\/full\/10.1021\/acs.jpcb.1c00869.","DOI":"10.1021\/acs.jpcb.1c00869"},{"key":"9553_CR42","doi-asserted-by":"crossref","unstructured":"Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. bioRxiv. 2021 [cited 2023 Nov 5];2021.01.13.426558. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.01.13.426558v1.","DOI":"10.1101\/2021.01.13.426558"},{"key":"9553_CR43","doi-asserted-by":"crossref","unstructured":"Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife. 2021 [cited 2023 Nov 5];10. Available from: https:\/\/elifesciences.org\/articles\/70658.","DOI":"10.7554\/eLife.70658"},{"key":"9553_CR44","doi-asserted-by":"crossref","unstructured":"Tchesnokova V, Kulasekara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al. Acquisition of the L452R mutation in the ACE2-binding interface of spike protein triggers recent massive expansion of SARS-CoV-2 variants. Mellmann A, editor. J Clin Microbiol. 2021 [cited 2023 Nov 5];59:e0092121. Available from: https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00921-21.","DOI":"10.1128\/JCM.00921-21"},{"key":"9553_CR45","unstructured":"Saito A, Irie T, Suzuki R, Maemura T, Uriu K, Kosugi Y, et al. SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion. 2021 [cited 2023 Nov 5]; Available from: https:\/\/europepmc.org\/article\/PPR\/PPR358614."},{"key":"9553_CR46","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMc2009324","volume":"382","author":"M Meselson","year":"2020","unstructured":"Meselson M. Droplets and aerosols in the transmission of SARS-CoV-2. N Engl J Med. 2020;382:2063\u20132063.","journal-title":"N Engl J Med"},{"key":"9553_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2020.105730","volume":"139","author":"L Morawska","year":"2020","unstructured":"Morawska L, Cao J. Airborne transmission of SARS-CoV-2: the world should face the reality. Environ Int. 2020;139: 105730.","journal-title":"Environ Int"},{"key":"9553_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13756-020-00763-0","volume":"9","author":"R Sommerstein","year":"2020","unstructured":"Sommerstein R, Fux CA, Vuichard-Gysin D, Abbas M, Marschall J, Balmelli C, et al. Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19. Antimicrob Resist Infect Control. 2020;9:100.","journal-title":"Antimicrob Resist Infect Control"},{"key":"9553_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2020.106039","volume":"144","author":"S Tang","year":"2020","unstructured":"Tang S, Mao Y, Jones RM, Tan Q, Ji JS, Li N, et al. Aerosol transmission of SARS-CoV-2? Evidence, prevention and control. Environ Int. 2020;144: 106039.","journal-title":"Environ Int"},{"key":"9553_CR50","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMc2004973","volume":"382","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564\u20137.","journal-title":"N Engl J Med"},{"key":"9553_CR51","doi-asserted-by":"publisher","unstructured":"Kumar R, Verma H, Singhvi N, Sood U, Gupta V, Singh M, et al. Comparative genomic analysis of rapidly evolving SARS-CoV-2 reveals mosaic pattern of phylogeographical distribution. mSystems. 2020;5. https:\/\/doi.org\/10.1128\/mSystems.00505-20.","DOI":"10.1128\/mSystems.00505-20"},{"key":"9553_CR52","doi-asserted-by":"crossref","unstructured":"Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2020;1866:165878.","DOI":"10.1016\/j.bbadis.2020.165878"},{"key":"9553_CR53","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","volume":"77","author":"BJ Bosch","year":"2003","unstructured":"Bosch BJ, van der Zee R, de Haan CAM, Rottier PJM. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77:8801\u201311.","journal-title":"J Virol"},{"key":"9553_CR54","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.","journal-title":"Nat Commun"},{"key":"9553_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.","journal-title":"Cell"},{"key":"9553_CR56","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.1128\/JVI.72.10.7885-7894.1998","volume":"72","author":"F Fischer","year":"1998","unstructured":"Fischer F, Stegen CF, Masters PS, Samsonoff WA. Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly. J Virol. 1998;72:7885\u201394.","journal-title":"J Virol"},{"key":"9553_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1006\/viro.1996.0165","volume":"218","author":"ECW Bos","year":"1996","unstructured":"Bos ECW, Luytjes W, van der Meulen H, Koerten HK, Spaan WJM. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology. 1996;218:52\u201360.","journal-title":"Virology."},{"key":"9553_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","volume":"174","author":"BW Neuman","year":"2011","unstructured":"Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174:11\u201322.","journal-title":"J Struct Biol"},{"key":"9553_CR59","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1128\/JVI.74.11.4967-4978.2000","volume":"74","author":"CAM de Haan","year":"2000","unstructured":"de Haan CAM, Vennema H, Rottier PJM. Assembly of the coronavirus envelope: homotypic interactions between the M proteins. J Virol. 2000;74:4967\u201378.","journal-title":"J Virol"},{"key":"9553_CR60","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1080\/07391102.2020.1861983","volume":"40","author":"R Mahtarin","year":"2022","unstructured":"Mahtarin R, Islam S, Islam MdJ, Ullah MO, Ali MA, Halim MA. Structure and dynamics of membrane protein in SARS-CoV-2. J Biomol Struct Dyn. 2022;40:4725\u201338.","journal-title":"J Biomol Struct Dyn."},{"key":"9553_CR61","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","volume":"11","author":"X Lei","year":"2020","unstructured":"Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810.","journal-title":"Nat Commun"},{"key":"9553_CR62","doi-asserted-by":"crossref","unstructured":"Li J, Feng J, Liu T, Xu F, Song G. An infant with a mild SARS-CoV-2 infection detected only by anal swabs: a case report. Braz J Infect Dis. 2020 [cited 2023 Nov 5];24:247\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S141386702030043X.","DOI":"10.1016\/j.bjid.2020.04.009"},{"key":"9553_CR63","doi-asserted-by":"crossref","unstructured":"Xiong C, Jiang L, Chen Y, Jiang Q. Evolution and variation of 2019-novel coronavirus. Biorxiv. 2020.01.30.926477.","DOI":"10.1101\/2020.01.30.926477"},{"key":"9553_CR64","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/nsr\/nwaa036","volume":"7","author":"X Tang","year":"2020","unstructured":"Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020;7:1012\u201323.","journal-title":"Natl Sci Rev"},{"key":"9553_CR65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281-292.e6.","journal-title":"Cell"},{"issue":"367","key":"9553_CR66","first-page":"1260","volume":"2020","author":"D Wrapp","year":"1979","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 1979;2020(367):1260\u20133.","journal-title":"Science"},{"key":"9553_CR67","doi-asserted-by":"publisher","first-page":"12910","DOI":"10.1074\/jbc.REV120.013930","volume":"295","author":"E Hartenian","year":"2020","unstructured":"Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. The molecular virology of coronaviruses. J Biol Chem. 2020;295:12910\u201334.","journal-title":"J Biol Chem"},{"key":"9553_CR68","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/CCM.0000000000004895","volume":"49","author":"CM Coopersmith","year":"2021","unstructured":"Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The surviving sepsis campaign: research priorities for coronavirus disease 2019 in critical illness. Crit Care Med. 2021;49:598\u2013622.","journal-title":"Crit Care Med"},{"key":"9553_CR69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108:17\u201341.","journal-title":"J Leukoc Biol"},{"key":"9553_CR70","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/all.14364","volume":"75","author":"AK Azkur","year":"2020","unstructured":"Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Br\u00fcggen M, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564\u201381.","journal-title":"Allergy"},{"key":"9553_CR71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The Lancet. 2020;395:497\u2013506.","journal-title":"China The Lancet"},{"key":"9553_CR72","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1093\/eurheartj\/ehaa253","volume":"41","author":"A Hua","year":"2020","unstructured":"Hua A, O\u2019Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020;41:2130\u20132130.","journal-title":"Eur Heart J"},{"key":"9553_CR73","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811.","journal-title":"JAMA Cardiol"},{"key":"9553_CR74","doi-asserted-by":"publisher","unstructured":"Chen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol. 2021;11. https:\/\/doi.org\/10.3389\/fneur.2020.573095.","DOI":"10.3389\/fneur.2020.573095"},{"key":"9553_CR75","doi-asserted-by":"publisher","unstructured":"Kumari N, Kumari R, Dua A, Singh M, Kumar R, Singh P, et al. From gut to hormones: unraveling the role of gut microbiota in (phyto)estrogen modulation in health and disease. Mol Nutr Food Res. 2024;68. https:\/\/doi.org\/10.1002\/mnfr.202300688.","DOI":"10.1002\/mnfr.202300688"},{"key":"9553_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104386","volume":"128","author":"KP Patel","year":"2020","unstructured":"Patel KP, Patel PA, Vunnam RR, Hewlett AT, Jain R, Jing R, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020;128: 104386.","journal-title":"J Clin Virol"},{"key":"9553_CR77","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.cgh.2020.09.041","volume":"19","author":"BJ Elmunzer","year":"2021","unstructured":"Elmunzer BJ, Spitzer RL, Foster LD, Merchant AA, Howard EF, Patel VA, et al. Digestive manifestations in patients hospitalized with coronavirus disease 2019. Clin Gastroenterol Hepatol. 2021;19:1355-1365.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9553_CR78","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00134-020-06153-9","volume":"46","author":"P Gabarre","year":"2020","unstructured":"Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46:1339\u201348.","journal-title":"Intensive Care Med"},{"key":"9553_CR79","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.kint.2020.05.006","volume":"98","author":"JS Hirsch","year":"2020","unstructured":"Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209\u201318.","journal-title":"Kidney Int"},{"key":"9553_CR80","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/liv.14435","volume":"40","author":"L Xu","year":"2020","unstructured":"Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998\u20131004.","journal-title":"Liver Int"},{"key":"9553_CR81","doi-asserted-by":"publisher","unstructured":"Baraniuk C. Covid-19: how the UK vaccine rollout delivered success, so far. BMJ. 2021;n421. https:\/\/doi.org\/10.1136\/bmj.n421.","DOI":"10.1136\/bmj.n421"},{"key":"9553_CR82","doi-asserted-by":"publisher","first-page":"138","DOI":"10.59118\/VQAR2242","volume":"2","author":"K Aditi","year":"2023","unstructured":"Aditi K, Kumari N, Singh P, Kumari A, Yadav Deen S, Kumar R. Comprehensive review of the initial 11 WHO emergency use listed COVID-19 vaccine candidates: mechanisms, efficacy, and comparative attributes for safety and well-being. Microsphere. 2023;2:138\u201358.","journal-title":"Microsphere"},{"key":"9553_CR83","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMe2110605","volume":"385","author":"SJW Evans","year":"2021","unstructured":"Evans SJW, Jewell NP. Vaccine effectiveness studies in the field. N Engl J Med. 2021;385:650\u20131.","journal-title":"N Engl J Med"},{"key":"9553_CR84","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","volume":"69","author":"SE Oliver","year":"2020","unstructured":"Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine \u2014 United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1922\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9553_CR85","volume-title":"WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. Geneva (Switzerland): World Health Organization; 2021."},{"key":"9553_CR86","unstructured":"OurWorldInData. Coronavirus (COVID-19) vaccinations. United Kingdom: OurWorldInData. 2021."},{"key":"9553_CR87","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"9553_CR88","unstructured":"Food Drug Administration U. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine. Silver Spring (MD): US Food and Drug Administration; 2020."},{"key":"9553_CR89","doi-asserted-by":"publisher","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","volume":"70","author":"DK Shay","year":"2021","unstructured":"Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine \u2014 United States, March\u2013April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:680\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9553_CR90","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.15585\/mmwr.mm695152e2","volume":"69","author":"K Dooling","year":"2021","unstructured":"Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The Advisory Committee on Immunization Practices\u2019 updated interim recommendation for allocation of COVID-19 vaccine \u2014 United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1657\u201360.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9553_CR91","volume-title":"Vector-based vaccines come to the fore in the COVID-19 pandemic","author":"A King","year":"2020","unstructured":"King A. Vector-based vaccines come to the fore in the COVID-19 pandemic. Wilmington (DE): Group Publishing; 2020."},{"key":"9553_CR92","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397:671\u201381.","journal-title":"The Lancet"},{"key":"9553_CR93","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41586-021-01813-2","volume":"595","author":"B Nogrady","year":"2021","unstructured":"Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021;595:339\u201340.","journal-title":"Nature"},{"key":"9553_CR94","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","volume":"397","author":"E Vasileiou","year":"2021","unstructured":"Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021;397:1646\u201357.","journal-title":"The Lancet"},{"key":"9553_CR95","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585\u201394.","journal-title":"N Engl J Med"},{"key":"9553_CR96","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386:340\u201350.","journal-title":"N Engl J Med"},{"key":"9553_CR97","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393\u2013400.","journal-title":"N Engl J Med"},{"key":"9553_CR98","unstructured":"European Centre for Disease Prevention and Control. Implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (omicron) for the EU\/EEA \u2014 first update. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/threat-assessment-covid-19-emergence-sars-cov-2-variant-omicron-december-2021.pdf. 2021."},{"key":"9553_CR99","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205\u201311.","journal-title":"Nat Med"},{"key":"9553_CR100","doi-asserted-by":"publisher","first-page":"103341","DOI":"10.1016\/j.isci.2021.103341","volume":"24","author":"T Tada","year":"2021","unstructured":"Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience. 2021;24:103341.","journal-title":"iScience."},{"key":"9553_CR101","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532\u201346.","journal-title":"N Engl J Med"},{"key":"9553_CR102","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187\u20139.","journal-title":"N Engl J Med"},{"key":"9553_CR103","doi-asserted-by":"crossref","unstructured":"Galvani A, Moghadas SM, Schneider EC. Deaths and hospitalizations averted by rapid U.S. vaccination rollout. The Commonwealth Fund, Issue Briefs. 2021.","DOI":"10.1101\/2021.07.07.21260156"},{"key":"9553_CR104","unstructured":"Public Health England. Direct and indirect impact of the vaccination programme on COVID-19 infections and mortality. (https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/997495\/Impact_of_COVID-19_vaccine_on_infection_and_mortality.pdf). 2021."},{"key":"9553_CR105","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","volume":"12","author":"D Lapuente","year":"2021","unstructured":"Lapuente D, Fuchs J, Willar J, Vieira Ant\u00e3o A, Eberlein V, Uhlig N, et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. 2021;12:6871.","journal-title":"Nat Commun"},{"key":"9553_CR106","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","volume":"22","author":"EC Lavelle","year":"2022","unstructured":"Lavelle EC, Ward RW. Mucosal vaccines \u2014 fortifying the frontiers. Nat Rev Immunol. 2022;22:236\u201350.","journal-title":"Nat Rev Immunol"},{"key":"9553_CR107","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"9553_CR108","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","volume":"8","author":"AF Hern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep. 2021;8:871\u20139.","journal-title":"Toxicol Rep"},{"key":"9553_CR109","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1136\/jnnp-2021-326984","volume":"92","author":"T Al-Mayhani","year":"2021","unstructured":"Al-Mayhani T, Saber S, Stubbs MJ, Losseff NA, Perry RJ, Simister RJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry. 2021;92:1247\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9553_CR110","doi-asserted-by":"publisher","unstructured":"Mushtaq HA, KhedrA, KoritalaT, Bartlett BN, Jain NK, Khan SA. A review of adverse effects of COVID-19 vaccines. Infez Med. 2022;30. https:\/\/doi.org\/10.53854\/liim-3001-1.","DOI":"10.53854\/liim-3001-1"},{"key":"9553_CR111","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. The Lancet. 2020;396:467\u201378.","journal-title":"The Lancet"},{"key":"9553_CR112","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/vaccines10030349","volume":"10","author":"PP Piccaluga","year":"2022","unstructured":"Piccaluga PP, Di Guardo A, Lagni A, Lotti V, Diani E, Navari M, et al. COVID-19 vaccine: between myth and truth. Vaccines (Basel). 2022;10:349.","journal-title":"Vaccines (Basel)"},{"key":"9553_CR113","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1182\/blood.2021011958","volume":"138","author":"A Tiede","year":"2021","unstructured":"Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021;138:350\u20133.","journal-title":"Blood"},{"key":"9553_CR114","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7861\/clinmed.2021-0321","volume":"22","author":"A Wills","year":"2022","unstructured":"Wills A, Swallow G, Kirkman MA, Rajan K, Subramanian G. Arterial and venous thrombotic stroke after ChAdOx1 nCoV-19 vaccine. Clin Med. 2022;22:184\u20136.","journal-title":"Clin Med"},{"key":"9553_CR115","first-page":"1","volume":"2022","author":"G Berlot","year":"2022","unstructured":"Berlot G, Tomasini A, La Fata C, Pintacuda S, Rigutti S, Falanga A. Widespread arterial thrombosis after ChAdOx1 nCov-19 vaccination. Case Rep Crit Care. 2022;2022:1\u20134.","journal-title":"Case Rep Crit Care"},{"key":"9553_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00872-2","volume":"397","author":"A Bayas","year":"2021","unstructured":"Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. The Lancet. 2021;397: e11.","journal-title":"The Lancet"},{"key":"9553_CR117","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2021."},{"key":"9553_CR118","doi-asserted-by":"publisher","unstructured":"Pavord S, Hunt BJ, Horner D, Bewley S, Karpusheff J. Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance. BMJ. 2021;n2195. https:\/\/doi.org\/10.1136\/bmj.n2195.","DOI":"10.1136\/bmj.n2195"},{"key":"9553_CR119","unstructured":"Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine\u2014weekly summary of Yellow Card reporting. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting. 2021."},{"key":"9553_CR120","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/vaccines10020232","volume":"10","author":"C de Gregorio","year":"2022","unstructured":"de Gregorio C, Colarusso L, Calcaterra G, Bassareo PP, Ieni A, Mazzeo AT, et al. Cerebral venous sinus thrombosis following COVID-19 vaccination: analysis of 552 worldwide cases. Vaccines (Basel). 2022;10:232.","journal-title":"Vaccines (Basel)"},{"key":"9553_CR121","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","volume":"32","author":"P Haber","year":"2009","unstructured":"Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barr\u00e9 syndrome. Drug Saf. 2009;32:309\u201323.","journal-title":"Drug Saf"},{"key":"9553_CR122","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/brain\/awaa444","volume":"144","author":"MP Lunn","year":"2021","unstructured":"Lunn MP, Cornblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, et al. COVID-19 vaccine and Guillain-Barr\u00e9 syndrome: let\u2019s not leap to associations. Brain. 2021;144:357\u201360.","journal-title":"Brain"},{"key":"9553_CR123","doi-asserted-by":"publisher","unstructured":"Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.13426.","DOI":"10.7759\/cureus.13426"},{"key":"9553_CR124","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines \u2014 a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"9553_CR125","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","volume":"144","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471\u201384.","journal-title":"Circulation"},{"key":"9553_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105906","volume":"30","author":"L Dias","year":"2021","unstructured":"Dias L, Soares-dos-Reis R, Meira J, Ferr\u00e3o D, Soares PR, Pastor A, et al. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J Stroke Cerebrovasc Dis. 2021;30: 105906.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"9553_CR127","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2940","volume":"5","author":"TM Tu","year":"2022","unstructured":"Tu TM, Yi SJ, Koh JS, Saffari SE, Hoe RHM, Chen GJ, et al. Incidence of cerebral venous thrombosis following SARS-CoV-2 infection vs mRNA SARS-CoV-2 vaccination in Singapore. JAMA Netw Open. 2022;5: e222940.","journal-title":"JAMA Netw Open"},{"key":"9553_CR128","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.7326\/L21-0244","volume":"174","author":"S Sangli","year":"2021","unstructured":"Sangli S, Virani A, Cheronis N, Vannatter B, Minich C, Noronha S, et al. Thrombosis with thrombocytopenia after the messenger RNA\u20131273 vaccine. Ann Intern Med. 2021;174:1480\u20132.","journal-title":"Ann Intern Med"},{"key":"9553_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2020.108499","volume":"331","author":"A Danchin","year":"2021","unstructured":"Danchin A, Turinici G. Immunity after COVID-19: protection or sensitization? Math Biosci. 2021;331: 108499.","journal-title":"Math Biosci"},{"key":"9553_CR130","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","volume":"397","author":"C Manisty","year":"2021","unstructured":"Manisty C, Otter AD, Treibel TA, McKnight \u00c1, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. The Lancet. 2021;397:1057\u20138.","journal-title":"The Lancet"},{"key":"9553_CR131","doi-asserted-by":"crossref","unstructured":"Krammer F, Srivastava K, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv 2021.01.29.21250653","DOI":"10.1101\/2021.01.29.21250653"},{"key":"9553_CR132","doi-asserted-by":"publisher","unstructured":"Wise J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ. 2021;n308. https:\/\/doi.org\/10.1136\/bmj.n308.","DOI":"10.1136\/bmj.n308"},{"key":"9553_CR133","doi-asserted-by":"publisher","unstructured":"Rustagi V, Bajaj M, Tanvi, Singh P, Aggarwal R, AlAjmi MF, et al. Analyzing the effect of vaccination over COVID cases and deaths in Asian countries using machine learning models. Front Cell Infect Microbiol. 2022;11. https:\/\/doi.org\/10.3389\/fcimb.2021.806265.","DOI":"10.3389\/fcimb.2021.806265"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-024-09553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-024-09553-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-024-09553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:03:47Z","timestamp":1770192227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-024-09553-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9553"],"URL":"https:\/\/doi.org\/10.1007\/s12026-024-09553-x","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}